1. Introduction {#sec1-jcm-08-01075}
===============

Delirium is an acute neuropsychiatric syndrome that often presents as a complication of generalized infection, hypoxia, surgery, effect of various medications, or acute stroke, especially in elderly patients \[[@B1-jcm-08-01075],[@B2-jcm-08-01075],[@B3-jcm-08-01075]\]. It is characterized by rapid onset, significant fluctuation of symptoms throughout the day, disturbance of the wake and sleep cycle, as well as changes in thinking, memory, and behavior \[[@B4-jcm-08-01075]\]. Post-stroke delirium is a well-described medical problem with long-term consequences of increased mortality and morbidity \[[@B5-jcm-08-01075]\]. The incidence of delirium in stroke patients ranges from 12% to 66%, depending on the diagnostic method used \[[@B6-jcm-08-01075],[@B7-jcm-08-01075],[@B8-jcm-08-01075]\]. A recently published prospective delirium study on ischemic brain stroke showed that the delirium frequency was 14.6% in the first week after admission \[[@B9-jcm-08-01075]\]. In the Polish population, delirium associated with acute ischemic stroke (AIS) was diagnosed in approximately 30% of patients \[[@B10-jcm-08-01075],[@B11-jcm-08-01075]\].

It is recommended that delirium is actively screened for with dedicated psychometric tools, including CAM-ICU (Confusion Assessment Method for Intensive Care Unit) and ICDSC (Intensive Care Delirium Screening Checklist) \[[@B1-jcm-08-01075],[@B12-jcm-08-01075],[@B13-jcm-08-01075]\]. Mitasova et al. reported that an episode of delirium was detected in 43% of patients with stroke using CAM-ICU monitoring \[[@B14-jcm-08-01075]\]. Delirium in stroke patients may be regarded as more difficult to diagnose and differentiate from new-onset neurological symptoms. However, the validity of CAM-ICU to diagnose delirium in ischemic stroke patients has been confirmed by multiple studies \[[@B14-jcm-08-01075],[@B15-jcm-08-01075]\].

Delirium is a clinical diagnosis, but a search for easily accessible and reliable serum biomarkers of this acute brain dysfunction is ongoing \[[@B16-jcm-08-01075]\]. The pathophysiology of delirium is not entirely understood, but many interrelated disorders of homeostasis are involved, including neuroinflammation and the effect of oxidative stress \[[@B17-jcm-08-01075],[@B18-jcm-08-01075]\]. Considering the inflammatory pathomechanism of delirium, researchers are looking for new diagnostic and prognostic biomarkers in the group of inflammatory factors. However, research in this area is extremely limited, and the results are conflicting. Inflammatory markers investigated in scientific studies have been associated with delirium, but their use in clinical practice is precluded by price and the difficulty of the diagnostic process. Simple laboratory parameters, easily available in every health care facility, performed in all patients at admission are in renaissance at the moment. Differential white blood cell count can be done with the use of any automated hematology analyzer as part of routine blood tests performed at admission.

Immune system activation seems to be the basis for delirium in acute neurological disorders, such as neuroinfections, trauma, and stroke. The neutrophil-to-lymphocyte ratio (NLR), which is a parameter derived from the differential white blood cell count, is a readily available marker of both inflammation and oxidative stress. It has recently been reported by Egberts at al. to be increased in elderly patients with delirium \[[@B19-jcm-08-01075]\].

In many recent studies, the NLR has been used and validated as an inflammatory marker, especially in cardiovascular disorders and malignancies. Celikbilek et al. showed that NLR in peripheral blood can serve as a simple systemic inflammatory response (SIR) marker that possesses a diagnostic value in certain diseases characterized by systemic or local inflammatory response \[[@B20-jcm-08-01075]\]. NLR is an indicator of the overall inflammatory status of the body, such as diabetes mellitus, coronary artery disease (CAD), ulcerative colitis, or inflammatory arthritis \[[@B21-jcm-08-01075],[@B22-jcm-08-01075],[@B23-jcm-08-01075],[@B24-jcm-08-01075]\]. Studies have shown that the NLR index is a good predictor of outcome in neurological and psychiatric conditions, such as Alzheimer's disease, Parkinson's disease, ischemic stroke, schizophrenia, and memory disorders, or after endarterectomy of the carotid arteries \[[@B25-jcm-08-01075],[@B26-jcm-08-01075],[@B27-jcm-08-01075],[@B28-jcm-08-01075]\].

The aim of this study was to investigate whether NLR could serve as a potential marker for delirium prediction in patients with AIS and to find an easy diagnostic tool using laboratory and clinical parameters to predict delirium.

2. Materials and Methods {#sec2-jcm-08-01075}
========================

2.1. Data Collection {#sec2dot1-jcm-08-01075}
--------------------

A retrospective analysis of prospectively collected data was carried out on 1022 consecutive adult patients (age \> 18 years) with acute ischemic stroke that were admitted to the neurology department of a busy district general hospital in Poland between 30 June 2015 and 31 March 2018. Patients with AIS were admitted to the neurology department within 48 hours of symptom development. The data was prospectively collected by a dedicated member of staff and included the following: complete past medical history and clinical and neurological evaluation, stroke severity according to the National Institute of Health Stroke Scale (NIHSS), degree of disability according to the modified Rankin scale (mRS), carotid artery ultrasonography, brain computed tomography (CT), and laboratory results, including full blood count (with differential white blood cell count) and C-reactive protein (CRP). All patients underwent routine blood analysis at admission using a fully automated cell counter in the local hematology laboratory to acquire complete blood count, including absolute neutrophil count, absolute lymphocyte count, and platelet count. The NLR was calculated by dividing the absolute neutrophil count over the absolute lymphocyte count from the same sample. We excluded patients with hematology disorders (5 patients), incomplete laboratory testing (6 patients), or no data regarding follow-up (10). The follow-up data was extracted from medical records and using a telephone contact at 30 days and 1 year after discharge to determine mortality at predefined timepoints. The primary end point was delirium diagnosed within 24 hours from admission in patients with acute ischemic stroke.

2.2. Delirium Monitoring {#sec2dot2-jcm-08-01075}
------------------------

We used the Polish version of the CAM-ICU assessment tool to screen all patients for delirium at admission and on a daily basis after admission to the hospital \[[@B13-jcm-08-01075]\]. To aid delirium diagnosis, a review of medical and nursing notes for a full evaluation of delirium was performed by one of the investigators. Delirium was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition \[[@B4-jcm-08-01075]\]. Delirium was defined as "early onset" if it was diagnosed within the first 24 hours after admission to the neurology unit due to acute ischemic stroke.

2.3. Ethical Consideration {#sec2dot3-jcm-08-01075}
--------------------------

The study was performed in accordance with the Declaration of Helsinki. We obtained approval of the Bioethical Committee of the Pomeranian Medical University, no. KBE-0012/84/03/19. The requirement for informed consent was waived as all data collected in the study was part of a routine clinical process performed in every AIS patient at admission to the hospital. The data was analyzed anonymously. This study was retrospectively registered at the ClinicalTrials.gov website, identifier number NCT03944694.

2.4. Statistical Analysis {#sec2dot4-jcm-08-01075}
-------------------------

The data are presented as mean and standard deviation for continuous variables and number and a percentage for categorical variables. We divided the acute ischemic stroke patients according to the absence or presence of delirium on admission (no delirium group vs. delirium group). Chi-square test or chi-square test with Yates correction was used to compare qualitative data between two groups of patients. The Mann--Whitney *U* test was used to compare continuous variables. The receiver operating characteristic (ROC) curve analysis was performed to determine the best cut-off value for predicting the clinical end points. Logistic regression analysis was performed, with additional correction for potentially interfering variables (age, sex, and body mass index (BMI)). On the basis of this regression, the parameters most closely related to the occurrence of delirium were sought. Based on a multifactorial model, information on the impact of each variable on delirium was obtained. Next, the contribution of each analyzed variable was calculated, and the formula was presented using elements with which the delirium score was calculated. *p*-value ≤ 0.05 was considered significant. All analyses were performed using licensed software Statistica 13 (StatSoft, Inc., Tulsa, OK, USA).

3. Results {#sec3-jcm-08-01075}
==========

We included 1001 patients in the final analysis with a complete set of data. The mean age of the sample was 71 years, with 52% of patients being men. The incidence of delirium on admission was 17.2% (172/1001 patients), and we therefore performed a comparative analysis between the subgroups (delirium vs. no delirium). Patients with delirium were older (*p* \< 0.001), more often presented with coexisting ischemic heart disease (*p* = 0.003), previous ischemic stroke (*p* = 0.017), impaired glucose tolerance (*p* \< 0.001), atrial fibrillation (*p* \< 0.001), and peripheral vascular disease (*p* \< 0.001), as shown in [Table 1](#jcm-08-01075-t001){ref-type="table"}.

Neurological findings in the study group are shown in [Table 2](#jcm-08-01075-t002){ref-type="table"}. Patients with delirium were more severely ill on admission, with higher NIHSS score (18.00 (12.00--21.50) vs. 8.00 (4.00--14.00), *p* \< 0.001) and Rankin score (5.00 (4.00--5.00) vs. 3.00 (1.00--4.00), *p* \< 0.001). Delirious patients presented with more amaurosis fugax (73.84% vs. 29.19%, *p* \< 0.001) and dysphasia (65.70% vs. 52.35%, *p* = 0.001) and more often had lesions \>2.5 cm (*p* \< 0.001). A majority of delirious patients presented with stroke from middle cerebral artery area (82.35% vs. 62.56%, *p* \< 0.001) and 50--70% carotid artery stenosis (38.41% vs. 20.99%, *p* \< 0.001).

The outcome data is shown in [Table 3](#jcm-08-01075-t003){ref-type="table"}. Patients presenting with delirium had longer hospital stay (10.00 (8.00--14.00) days vs. 9.00 (8.00--11.00) days, *p* \< 0.001) and higher mortality at day 7 (15.7% vs. 4.95%, *p* \< 0.001), at day 30 (38.4% vs. 12.2%, *p* \< 0.001), and at one year (23.8% vs. 61.2%, *p* \< 0.001). A smaller percentage of AIS patients were discharged home (41.3% vs. 61.9%, *p* \< 0.001) or to a rehabilitation center (17.4% vs. 21.1%, *p* \< 0.001) if they had delirium on admission.

Mean levels and standard deviations of laboratory markers adjusted for age and sex are shown in [Table 4](#jcm-08-01075-t004){ref-type="table"}. In delirious patients, the total leucocyte count was higher (*p* = 0.006), as was the neutrophil count (*p* \< 0.001), but the lymphocyte count was lower (*p* = 0.006), giving a higher neutrophil-to-lymphocyte ratio (3.92 (2.44--7.87) vs. 3.14 (2.06--5.09), *p* \< 0.001). The CRP level was also higher in delirious patients (7.58 (2.25--30.00) vs. 3.00 (1.10--9.69), *p* \< 0.001).

Our aim was to investigate which laboratory markers could serve as diagnostic markers for delirium. For this, we performed a ROC analysis for leucocyte, neutrophil, lymphocyte count, the derived parameter NLR, and CRP to predict early-onset delirium in AIS patients, as shown in [Figure 1](#jcm-08-01075-f001){ref-type="fig"}.

The details regarding area under the curve (AUC), sensitivity, and specificity for each marker are shown in [Table 5](#jcm-08-01075-t005){ref-type="table"}.

Because patients with delirium had significantly higher values of NLR at admission, we decided to perform a ROC analysis to calculate the best cut-off value to predict delirium, as shown in [Figure 2](#jcm-08-01075-f002){ref-type="fig"}. The best cut-off value was 4.86, with an AUC of 0.597 (95% CI 0.549--0.644, *p* \< 0.001).

Multivariable logistic regression analysis adjusted according to age, sex, BMI, comorbidities, and baseline neurology showed that leucocyte count (*p* \< 0.001) and neutrophil count (*p* = 0.012) as well as mean NRL (*p* = 0.028), NRL (*p* \< 0.001), and NLR at the predefined cut-off of \>4.86 (*p* \< 0.001) exhibited an association with post-stroke delirium after adjustment with baseline characteristics ([Table 6](#jcm-08-01075-t006){ref-type="table"}). For NLR \> 4.86 adjusted for age, sex, BMI, comorbidities, and baseline neurology, the odds ratio (OR) was 1.875 (95% CI 1.314--2.675, *p* = 0.001). Similar finding was noted regarding the CRP, with the cut-off \>9.10, for which the OR adjusted for age, sex, BMI, comorbidities, and baseline neurology was even higher with NLR at 2.132 (95% CI 1.482--3.066, *p* \< 0.001).

The AUC value for NLR as well as its sensitivity and specificity were moderate, so we decided to find a combination of markers and clinical parameters that would help predict the occurrence of early-onset delirium in AIS. Using clinical and laboratory factors, we determined that an index composed of age, NIHSS score, neurological findings, leucocyte count, NLR, and CRP was better at predicting early-onset delirium after acute ischemic stroke than any of the factors alone. To increase the diagnostic value of the laboratory markers in the study group, clinical and laboratory variables most associated with delirium were determined based on logistic regression. We calculated the score based on logistic regression for delirium in the whole study group as follows:

DELirium in Acute Ischemic Stroke (DELIAS) score = (1.272 × hemianopia) + (0.098 × aphasia) + (0.026 × age) + (0.054 × NIHSS score on admission) − (0.005 × NLR) + (0.028 × Leukocytes) + (0.001 × CRP).

On the basis of the obtained values, an ROC curve was determined. [Figure 3](#jcm-08-01075-f003){ref-type="fig"} depicts the ROC curve for the DELIAS score, calculated based on a formula derived from data of patients with early-onset delirium. The optimal AUC was 0.801, *p* \< 0.001, with very good sensitivity of 0.813 and specificity of 0.673. In this group, the DELIAS score can be regarded as a parameter with good predictive value for delirium prediction ([Table 7](#jcm-08-01075-t007){ref-type="table"}). To verify the predictability value of the DELIAS score for the diagnosis of delirium, we performed an ROC analysis for delirium diagnosed up to the fifth day in the same group of patients. In this case, the AUC was 0.725, *p* \< 0.001, with sensitivity of 0.901 and specificity of 0.477 ([Figure 4](#jcm-08-01075-f004){ref-type="fig"}). The DELIAS score had a good predictive value for early-onset delirium and moderate predictive value for delirium up to the fifth day from AIS.

Logistic regression analysis was performed for patients with early-onset delirium and for patients with delirium up to five days ([Table 8](#jcm-08-01075-t008){ref-type="table"}). The analysis was made on the basis of the cut-off points of the obtained formula. For patients with early-onset delirium, a significant correlation was shown with the delirium score (OR = 8.976, *p* \< 0.001). Similarly, a statistically significant correlation with the delirium score was demonstrated in patients presenting with delirium up to five days (OR = 7.744, *p* \< 0.001).

[Figure 5](#jcm-08-01075-f005){ref-type="fig"} shows a combination of factors and their predictive values for early-onset delirium as diagnosed using logistic regression, with DELIAS score showing the largest AUC.

4. Discussion {#sec4-jcm-08-01075}
=============

This study sought to determine if NLR is an early marker of delirium in patients with acute ischemic stroke. It is the largest prospective database evaluating the role of NLR as a prognostic marker for developing delirium in critically ill stroke patients. In the present study, we found that the mean levels of leukocytes and neutrophils were elevated, while those of lymphocytes were decreased in stroke patients with delirium. The NLR was elevated (6.39 ± 8.60 vs. 4.61 ± 5.61, *p* \< 0.001), yet AUC for NLR was 0.597, indicating modest predictive ability. Even at the optimal cut-off of 4.86, the sensitivity was 42% and specificity was 74%, making it not an ideal standalone test for the detection of delirium. Despite the fact that the NLR AUC is not very discriminative given the relatively low AUCs, our investigation adds an important piece of evidence on the relationship between delirium and a dysfunction of immune effector cells. The data regarding neutrophil, lymphocyte, and the neutrophil-to-lymphocyte ratio in delirium had previously been limited to a couple of studies.

The authors aimed to find a diagnostic score using easily accessible laboratory parameters to predict delirium after acute ischemic stroke. Adjusted multivariable logistic regression showed that, for NLR at the cut-off value \>4.86, the OR was 1.875 (95% CI 1.314--2.675, *p* = 0.001). For C-reactive protein, this association was even stronger, and for CRP at the cut-off value \>9.10, the OR was even higher than for NLR at 2.132 (95% CI 1.482--3.066, *p* \< 0.001).

Therefore, the authors would like to underline that using clinical and laboratory factors combined in one score composed of age, NIHSS score, neurological findings, leucocyte count, NLR, and CRP is better at predicting early-onset delirium after acute ischemic stroke than any of the factors alone.

The findings of this study regarding NLR, white blood cells differential count, and CRP suggest that an inadequate response of the immune system and oxidative stress may play a role in the pathogenesis of delirium. Studies have shown that inflammatory markers and cytokines (i.e., neopterine, interleukin-8) can be detected in the cerebrospinal fluid of delirious patients \[[@B29-jcm-08-01075],[@B30-jcm-08-01075],[@B31-jcm-08-01075]\]. Growing evidence suggests that neutrophils and lymphocytes are major effectors of acute inflammation \[[@B32-jcm-08-01075]\]. The initial response in generalized stress, including stroke, is a nonspecific activation of the immune system, where the first-line response is the increase in neutrophil count and a decrease in the lymphocyte count \[[@B32-jcm-08-01075],[@B33-jcm-08-01075]\]. This leads to a disruption of the neutrophil-to-lymphocyte ratio in peripheral circulation.

In agreement with our findings, Egberts et al., in a pilot study on a small sample of patients, also found that elevated levels of NLR were associated with delirium in elderly patients \[[@B19-jcm-08-01075]\]. In their study, 13 out of 86 patients were diagnosed with delirium and, using adjusted models, the authors showed that higher mean NLR values were found in patients with delirium (9.10 vs. 5.18, *p* = 0.003). The same study determined that the difference between the total number of leukocytes, neutrophils, and lymphocytes were not significant between patients with and without delirium. The authors suggested that only the right ratio, or a certain level of balance between neutrophils to lymphocytes, is important in the mechanism of delirium formation \[[@B19-jcm-08-01075]\]. In their study group, the NLR had a weak correlation with the level of CRP. Our analysis showed a similar correlation between NLR and CRP in patients with AIS and delirium on admission to hospital. It has been shown that CRP has at least as strong an association with delirium after ischemic stroke as NLR, but it is not always available to the clinician. It would be more interesting if a combination of markers would help predict the presence of delirium.

As previously mentioned, stress-induced physiological immune system response is defined by an increase in the neutrophil count and a concomittant decrease in the lymphocyte count \[[@B34-jcm-08-01075],[@B35-jcm-08-01075]\]. In delirium, elevated neutrophil count and NLR may reflect the degree of neuroinflammation and may be the basis of prediction of delirium by systemic inflammatory indicators \[[@B36-jcm-08-01075]\]. NLR is a novel inflammatory biomarker proposed as a prognostic factor in different inflammatory diseases, including systemic lupus erythematosus (SLE), ulcerative colitis, and inflammatory arthritis, as well as in metabolic disorder diabetes mellitus or coronary artery disease \[[@B26-jcm-08-01075],[@B37-jcm-08-01075]\]. NLR has previously been reported to be useful as a prognostic factor in acute ischemic stroke and transient ischemic attack \[[@B36-jcm-08-01075],[@B37-jcm-08-01075]\]. Recently, Wu et al. reported that leukocytosis may be regarded as an early pathology of subarachnoid hemorrhage and that NLR may be used as a practical predictor for the occurrence of delayed cerebral ischemia in those patients \[[@B38-jcm-08-01075]\]. A disturbance in peripheral blood lymphocyte subsets has been described to be associated with complications in high-risk vascular patients \[[@B39-jcm-08-01075]\].

Lymphocytes are regarded as the mediators of chronic inflammation. Therefore, in the acute phase of inflammation, their numbers decrease initially, while the number of neutrophils increases; at a later stage, the lymphocyte level increases. This phenomenon may be a part of age-associated chronic inflammation of low-grade chronic immune system response to aging (inflammaging) and age-related diseases, such as delirium \[[@B40-jcm-08-01075]\].

Lymphopenia and T-cell dysfunction are known predictors of mortality in ICU patients \[[@B36-jcm-08-01075]\]. Lymphopenia may be regarded as a nonspecific yet readily available bedside marker of immunosuppression. Inoue et al. examined whether lymphopenia was associated with the development of acute brain dysfunction (delirium and/or coma) or 30-day mortality in general medical and surgical ICU patients. Their research regarding the number of lymphocytes in delirium showed that the reduced number of lymphocytes did not affect the number of days with delirium or in coma in patients in the intensive care unit \[[@B41-jcm-08-01075]\]. The authors reported that patients with lower lymphocyte levels showed a trend toward higher chance of coma and delirium (*p* = 0.07), yet there was no significant relationship between lymphopenia and 30-day mortality \[[@B41-jcm-08-01075]\].

The definite strength of our study is the large number of patients with delirium and AIS and its prospective data collection. The sample size of 1001 patients is larger than most studies reported in the literature to date on the risk of developing delirium in patients with AIS. The out-of-research setting of a district general hospital shows that easily obtainable markers (NLR, CRP) can be used in a general population as bedside indicators of acute brain dysfunction. We also used C-reactive protein as a control for inflammation. Results from the present study have derived a more advanced prediction formula (the DELIAS score) than other measures that have been reported in the literature on delirium in AIS. Our model could be presented in terms of a proposal for the construction of a score, that is, based on our mathematical approach, conclusions can be drawn to design, at a later date, a score that is easy to apply in any context. NLR as the biomarker may have an advantage over other measures reported in the literature, with a much simpler approach for wider practice than those reported in the past.

Our study is not without limitations in terms of missing potential confounders, generalizability, or causative association between NLR and delirium. First, this is a single-center observation series in patients with acute ischemic stroke, and the results may not be applicable for other patients with delirium (ICU delirium, postoperative delirium, oncology patients). Second, we did not exclude patients using steroid therapy, and this may have had an influence on immune parameters. Third, we did not include white blood cell counts after admission as we were investigating the role of early factors available to guide the delirium diagnosis. This cut-off value for NLR was arrived at and not based on a standard value as no official standard cut-off for NLR currently exists. It would be necessary to perform an analysis regarding subtypes of white blood cells to determine the influence of immunity on different types of delirium in different settings. NLR seems to be a nonspecific marker and can be elevated in the context of a wide variety of conditions, such as cancer, diabetes, CAD, etc., even in the absence of delirium.

Despite these limitations, our study is the first study to evaluate the association between NLR and acute brain injury in patients with acute ischemic stroke. Further prospective multicenter studies in different settings are needed to evaluate the role of our preliminary conclusion.

5. Conclusions {#sec5-jcm-08-01075}
==============

In this study, we evaluated the association between laboratory markers, including NLR, and the presence of delirium in patients with acute ischemic stroke and found significantly higher values of NLR levels in patients with delirium compared to those without delirium. From this study, we can conclude that NLR can be used as a potential marker for prediction of early-onset delirium after acute ischemic stroke. On the basis of the combined laboratory and clinical parameters, a combination of parameters named the DELIAS score was determined, which showed the highest predictive values for delirium in the analyzed group of patients after ischemic stroke. The results of this study confirm that an inadequate response of the immune system may play a role in the pathogenesis of delirium after stroke.
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jcm-08-01075-t001_Table 1

###### 

Baseline characteristics of patients with acute ischemic stroke (AIS) with and without delirium.

  -------------------------------------------------------------------------------------------------------------------------
  Variables                                Total\                 No Delirium\           Delirium\              *p*-Value
                                           (*n* = 1001)           (*n* = 829)            (*n* = 172)            
  ---------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  **Demographic data**                                                                                          

  Age (years), Me (IQR)                    71.00 (64.00--82.00)   70.00 (63.00--81.00)   79.00 (67.50--87.00)   \<0.001

  Gender (male), *n* (%)                   523 (52.25)            445 (53.68)            78 (45.35)             0.047

  BMI (kg/m^2^), Me (IQR)                  26.03 (24.02--29.05)   25.95 (23.95--29.05)   26.64 (24.22--28.67)   0.496

  Smoking, *n* (%)                         417 (41.66)            343 (41.38)            74 (43.01)             0.689

  **Comorbidities**                                                                                             

  Arterial hypertension, *n* (%)           869 (86.81)            721 (86.97)            148 (86.05)            0.744

  Ischemic heart diseases, *n* (%)         258 (25.77)            198 (23.88)            60 (34.88)             0.003

  Myocardial infarction, *n* (%)           107 (10.69)            88 (10.62)             19 (11.05)             0.868

  Previous ischemic stroke, *n* (%)        222 (22.18)            172 (20.75)            50 (29.07)             0.017

  Previous hemorrhagic stroke, *n* (%)     24 (2.39)              23 (2.77)              1 (0.58)               0.151

  TIA last 30 days, *n* (%)                129 (12.89)            101 (12.18)            28 (16.28)             0.145

  TIA earlier than last 30 days, *n* (%)   107 (10.69)            83 (10.01)             24 (13.95)             0.128

  CT post-stroke lesions, *n* (%)          324 (32.37)            252 (30.4)             72 (41.86)             0.003

  Acute renal failure, *n* (%)             9 (0.89)               5 (0.6)                4 (2.33)               0.083

  Chronic renal failure, *n* (%)           143 (14.29)            109 (13.15)            34 (19.77)             0.024

  Dialysis, *n* (%)                        2 (0.19)               2 (0.24)               0 (0)                  0.769

  Impaired insulin tolerance, *n* (%)      48 (4.79)              29 (3.5)               19 (11.05)             \<0.001

  Diabetes (oral medications), *n* (%)     205 (20.48)            166 (20.02)            39 (22.67)             0.433

  Diabetes (insulin), *n* (%)              129 (12.89)            101 (12.2)             28 (16.28)             0.146

  Atrial fibrillation, *n* (%)             293 (29.27)            210 (25.36)            83 (48.26)             \<0.001

  AF paroxysmal, *n* (%)                   61 (6.09)              51 (6.15)              10 (5.81)              0.866

  AF persistent, *n* (%)                   163 (16.28)            107 (12.91)            56 (32.56)             \<0.001

  ICA stenosis, *n* (%)                    87 (8.69)              70 (38.67)             17 (47.22)             0.339

  LICA, Me (IQR)                           50 (0.0--50.0)         50 (0.0--50.0)         50 (0.0--50.0)         0.288

  RICA, Me (IQR)                           50 (0.0--50.0)         50 (0.0--50.0)         50 (0.0--50.0)         0.453

  COPD                                     95 (9.49)              77 (9.29)              18 (10.47)             0.632

  Peripheral vascular disease, *n* (%)     454 (45.35)            348 (41.98)            106 (61.63)            \<0.001
  -------------------------------------------------------------------------------------------------------------------------

Legend: *n*---number of patients, BMI---body mass index, TIA---transient ischemic attack, CT---computed tomography, AF---atrial fibrillation, ICA---internal carotid artery, LICA---left internal carotid artery, RICA---right internal carotid artery, COPD---chronic obstructive pulmonary disease, Me---median, IQR---interquartile range.

jcm-08-01075-t002_Table 2

###### 

Baseline neurology data for AIS patients with and without delirium.

  ---------------------------------------------------------------------------------------------------------
  Variables                              No Delirium\         Delirium\              *p*-Value    
                                         (*n* = 829)          (*n* = 172)                         
  -------------------------------------- -------------------- ---------------------- ------------ ---------
  NIHSS at admission, Me (IQR)           8.00 (4.00--14.00)   18.00 (12.00--21.50)   \<0.001      

  Rankin score at admission, Me (IQR)    3.00 (1.00--4.00)\   5.00 (4.00--5.00)\     \<0.001      
                                         2.86 ± 1.56          4.37 ± 1.12                         

  Hemianopia, *n* (%)                    242 (29.19)          127 (73.84)            \<0.001      

  Dysphasia, *n* (%)                     434 (52.35)          113 (65.70)            0.001        

  Brainstem stroke, *n* (%)              39 (4.70)            8 (4.65)               0.867        

  CT imaging-lesion, *n* (%)             No lesion            55 (6.63)              8 (4.65)     \<0.001

  Lesion \< 2.5 cm                       378 (45.60)          29 (16.86)                          

  Lesion \> 2.5 cm                       371 (44.75)          135 (78.49)                         

  Lacunar stroke                         25 (3.02)            0 (0)                               

  Cerebral artery involvement, *n* (%)   Anterior CA          186 (22.68)            9 (5.29)     \<0.001

  Middle CA                              513 (62.56)          140 (82.35)                         

  Posterior CA                           121 (14.76)          21 (12.35)                          

  Carotid artery stenosis, *n* (%)       No changes           29 (3.6)               3 (1.83)     \<0.001

  Up to 50%                              506 (62.86)          75 (45.73)                          

  50--70%                                169 (20.99)          63 (38.41)                          

  \>70%                                  50 (6.21)            6 (3.66)                            

  Occlusion                              51 (6.34)            17 (10.37)                          

  AIS treatment, *n* (%)                 Conservative         638 (80.35)            145 (84.8)   0.178

  Thrombolysis                           156 (19.65)          26 (15.20)                          
  ---------------------------------------------------------------------------------------------------------

Legend: NIHSS---National Institute of Health Stroke Scale, *n*---number of patients, CT---computed tomography, CA---cerebral artery, Me---median, IQR---interquartile range.
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###### 

Outcome for AIS patients with and without delirium.

  --------------------------------------------------------------------------------------------------------------------
  Variables                                     No Delirium\            Delirium\              *p*-Value     
                                                (*n* = 829)             (*n* = 172)                          
  --------------------------------------------- ----------------------- ---------------------- ------------- ---------
  Hospital LOS (days), Me (IQR)\                9.00 (8.00--11.0)\      10.00 (8.00--14.00)\   \<0.001       
  OR                                            0.977                   1.023                                

  Time from stroke to death (days), Me (IQR)\   29.00 (11.00--87.00)\   25.00 (8.00--50.00)\   0.161         
  OR                                            1.002                   0.998                                

  Rankin score at discharge, Me (IQR)\          2.00 (1.00--4.00)\      5.00 (3.00--5.00)\     \<0.001       
  OR                                            0.664                   1.506                                

  NIHSS at discharge, Me (IQR)\                 4.00 (2.00--12.00)\     18.00 (6.00--29.00)\   \<0.001       
  OR                                            0.951                   1.052                                

  Mortality at day 7, *n* (%)\                  41 (4.94)\              27 (15.69)\            \<0.001       
  OR                                            0.279                   3.579                                

  Mortality at day 30, *n* (%)\                 101 (12.18)\            66 (38.37)\            \<0.001       
  OR                                            0.223                   4.488                                

  Mortality at 1 year, *n* (%)\                 197 (23.76)\            107 (62.21)\           \<0.001       
  OR                                            0.189                   5.281                                

  Discharge                                     Death, *n* (%)\         67 (8.08)\             37 (21.51)\   \<0.001
                                                OR                      0.823                  1.215         

  Home, *n* (%)\                                513 (61.88)\            71 (41.28)\                          
  OR                                            3.990                   0.251                                

  Nursing home, *n* (%)\                        63 (7.60)\              29 (16.86)\                          
  OR                                            1.200                   0.834                                

  Rehabilitation center, *n* (%)\               175 (21.11)\            30 (17.44)\                          
  OR                                            3.221                   0.310                                

  Other, *n* (%)\                               11 (1.33)\              5 (2.91)\                            
  OR                                            1.215                   0.823                                
  --------------------------------------------------------------------------------------------------------------------

Legend: *n*---number of patients, OR---odds ratio, LOS---length of stay, NIHSS---National Institutes of Health Stroke Scale, Me---median.
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###### 

Laboratory values for AIS patients with and without delirium.

  ---------------------------------------------------------------------------------------------
  Variables                               No Delirium\         Delirium\            *p*-Value
                                          (*n* = 829)          (*n* = 172)          
  --------------------------------------- -------------------- -------------------- -----------
  Leucocyte count (×10^9^/L); Me (IQR)    8.97 (7.33--11.27)   9.73 (7.67--11.91)   0.006

  Neutrophil count (×10^9^/L); Me (IQR)   5.91 (4.47--7.92)    7.12 (4.99--9.52)    \<0.001

  Lymphocyte count (×10^9^/L); Me (IQR)   1.86 (1.38--2.46)    1.66 (1.13--2.31)    0.006

  NLR; Me (IQR)                           3.14 (2.06--5.09)    3.92 (2.44--7.87)    \<0.001

  CRP (mg/L); Me (IQR)                    3.00 (1.10--9.69)    7.58 (2.25--30.00)   \<0.001
  ---------------------------------------------------------------------------------------------

Note: Laboratory markers are adjusted for age and sex. Legend: *n*---number of patients, NLR---neutrophil-to-lymphocyte ratio, CRP---C-reactive protein, Me---median.
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###### 

Details of the receiver operating characteristics (ROC) analysis for white cell values and C-reactive protein (CRP).

  Variable     AUC     Youden's Index   Cut-Off Value   Sensitivity   Specificity   *p*-Value
  ------------ ------- ---------------- --------------- ------------- ------------- -----------
  Leucocyte    0.566   0.13             9.53            0.535         0.592         0.006
  Neutrophil   0.590   0.17             7.07            0.512         0.659         \<0.001
  Lymphocyte   0.567   0.13             1.23            0.308         0.823         0.008
  NLR          0.597   0.16             4.86            0.424         0.739         \<0.001
  CRP          0.644   0.22             9.10            0.476         0.746         \<0.001

Legend: AUC---area under the curve, NLR---neutrophil-to-lymphocyte ratio, CRP---C-reactive protein.
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###### 

Logistic regression analysis regarding inflammatory parameters according to the occurrence of delirium on admission in patients with acute ischemic stroke.

  Independent Variable          Unadjusted                       Adjusted               
  ----------------------------- ---------------------- --------- ---------------------- ---------
  Leucocyte count (×10^9^/L)    1.064 (1.026--1.103)   \<0.001   1.068 (1.028--1.110)   0.001
  Neutrophil count (×10^9^/L)   1.047 (1.010--1.085)   0.012     1.043 (1.003--1.084)   0.035
  Lymphocyte count (×10^9^/L)   0.918 (0.780--1.082)   0.307     0.959 (0.867--1.062)   0.424
  NLR (mean)                    1.036 (1.011--1.061)   0.005     1.025 (1.000--1.050)   0.049
  NLR \> 4.86                   2.056 (1.463--2.890)   \<0.001   1.875 (1.314--2.675)   0.001
  CRP                           1.007 (1.004--1.010)   \<0.001   1.006 (1.003--1.010)   \<0.001
  CRP \> 9.10                   2.662 (1.888--3.753)   \<0.001   2.132 (1.482--3.066)   \<0.001

Note: Variables were adjusted according to age, sex, BMI, comorbidities, and baseline neurology. Legend: OR---odds ratio, CI---confidence interval, NLR---neutrophil-to-lymphocyte ratio, CRP---C-reactive protein.
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###### 

Details of the DELirium in Acute Ischemic Stroke (DELIAS) score for early-onset delirium (up to 24 hours) and delirium up to 5 days.

                                                           AUC     Youden's Index   Cut-Off Value   Sensitivity   Specificity   *p*-Value
  -------------------------------------------------------- ------- ---------------- --------------- ------------- ------------- -----------
  DELIAS score for early-onset delirium (up to 24 hours)   0.801   0.50             3.358           0.813         0.673         \<0.001
  DELIAS score for delirium up to 5 days                   0.725   0.38             2.704           0.901         0.477         \<0.001
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###### 

Logistic regression analysis using DELIAS score to predict occurrence of delirium in patients with acute ischemic stroke.

                                                                                      OR (95% CI)             *p*-Value
  ----------------------------------------------------------------------------------- ----------------------- -----------
  DELIAS score for early-onset delirium (up to 24 hours) for cut-off point \> 3.358   8.976 (5.913--13.624)   \<0.001
  DELIAS score for delirium up to 5 days for cut-off point \> 2.704                   7.744 (4.531--13.234)   \<0.001
